The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 13, 2016
Filed:
Apr. 02, 2014
Applicants:
Jeffry G Weers, Belmont, CA (US);
Thomas E Tarara, Burlingame, CA (US);
Luis a Dellamary, San Marcos, CA (US);
Ernest G Schutt, San Diego, CA (US);
Inventors:
Jeffry G Weers, Belmont, CA (US);
Thomas E Tarara, Burlingame, CA (US);
Luis A Dellamary, San Marcos, CA (US);
Jean G Riess, Falicon, FR;
Ernest G Schutt, San Diego, CA (US);
Assignee:
Novartis AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/00 (2006.01); A61K 47/24 (2006.01); A61K 31/465 (2006.01); A61K 31/496 (2006.01); A61K 31/58 (2006.01); A61K 31/7036 (2006.01); A61K 31/7048 (2006.01); A61K 38/29 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 9/10 (2006.01); A61M 15/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/1617 (2013.01); A61K 9/008 (2013.01); A61K 9/0075 (2013.01); A61K 9/0082 (2013.01); A61K 9/14 (2013.01); A61K 9/1611 (2013.01); A61K 31/465 (2013.01); A61K 31/496 (2013.01); A61K 31/58 (2013.01); A61K 31/7036 (2013.01); A61K 31/7048 (2013.01); A61K 38/29 (2013.01); A61K 45/06 (2013.01); A61K 47/24 (2013.01); A61K 9/10 (2013.01); A61K 9/1694 (2013.01); A61K 47/02 (2013.01); A61M 15/0065 (2013.01); A61M 2205/3306 (2013.01);
Abstract
Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.